^
Association details:
| Biomarker: | Chr del(11q) + ATM mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Regimen: | BR (bendamustine + Rituxan (rituximab)) |
| Direction: | Resistant |
Evidence:
Source:
Title:
GENETIC ABERRATIONS AND PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED CHEMOIMMUNOTHERAPY (FCR/BR): CLINICAL PRACTICE EXPERIENCE
Published date:
05/17/2018
Excerpt:
To analyze progression-free survival (PFS) according to the presence of genetic defects in CLL patients treated with front line FCR or BR regimen...very short PFS in patients with sole 11q- (other ATM allele intact) (15 m vs. 28 m in ATM-wt patients and 30 m in ATM-mut patients; P = 0.052).
